Dr. Arvinder Soin discusses the use of tocilizumab plus standard care versus standard care alone in the treatment of moderate to severe COVID-19-associated cytokine release syndrome.  Read the full article: https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00081-3/fulltext

Dr. Arvinder Soin discusses the use of tocilizumab plus standard care versus standard care alone in the treatment of moderate to severe COVID-19-associated cytokine release syndrome. Read the full article: https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00081-3/fulltext

Dr. Arvinder Soin discusses the use of tocilizumab plus standard care versus standard care alone in the treatment of moderate to severe COVID-19-associated cytokine release syndrome.&nbsp; Read the full article: https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00081-3/fulltext

Tocilizumab and COVID-19

Editors speak to the journal’s authors to explore their research and its impact on people’s health, health care, and health policy in this regular podcast.

Share Tocilizumab and COVID-19

Sign up to save your podcasts

Tocilizumab and COVID-19

Tocilizumab and COVID-19